|
Post by cm5 on Jul 16, 2016 11:50:47 GMT -5
Re: question about non-endo physicians--
First, many physicians know a lot about many many subjects/issues than non-physicians would ever understand/acknowledge. The dedicated are beyond aware of the massive consequences of unaddressed/unrecognized/unsatisfactorily treated obesity, ingestion of heavily promoted/subsidized processed foods, and long term consequences of ongoing inflammation, which is constant with persistent and elevated blood glucose levels.
In particular, many physicians understand the consequences of untreated pre-diabetes and obesity. We know more than the general public realizes about Diabetes Type I, Pre-Diabetes (etc etc), Diabetes Type II, and Diabetes Type III.
BTW, Diabetes Type III = Alzheimer's disease specifically, and many other types of dementia, in general.
We are beyond frustrated/disappointed/and sad about what we see happening to human beings world wide.
And, we constantly are aware of the issues of "protocols", tedious data-keeping, tedious and time consuming work to get needed medication/treatments approved, and beyond constantly aware of ongoing monitoring/data keeping by every level of insurance industry/managed care industry/every level of governments/and constant vulnerability to complaints, official questioning of decisions made for human beings----to say nothing of those just looking for a way to gain financially in the legal systems.
So, when what seems to be a great modality/pharmaceutical/treatment appears, and there is no real education/back up effort by the manufacturer/pharmaceutical company/protocol setters, it is actually dangerous to prescribe without great education tools, patient literature, real pharmaceutical company patient support/education/nurse educators/process for approval for med, etc.
Long and short, from the perspective of many of us, Sanofi sabotaged Afrezza, Mannkind, and human beings in general.
Sanofi reps can say this only privately.
In short, the corporate level decisions, led by Olivier Brandicourt, constitute at best corporate malfeasance, and at the worse, unethical immoral behavior.
Believe it or not, many great pharmaceutical companies/researchers do seek to help people and the world with what they do. Yes, they do make profits whenever possible, but how on earth are they to pay for good employees/benefits/distribution/research without profits?
Honorable profit is absolutely possible.
|
|
|
Post by peppy on Jul 16, 2016 12:00:13 GMT -5
it is my understanding there are approximately 150 thousand Continuous Glucose Monitors being used? The money is in the tubing/sensor replacements.
quote: Despite MNKD 2.0 transparency not turning out to be as touted, I dont see any reason why MNKD cant announce that pursuit of a collaboration is central to the relaunch. We dont know if MNKD is or is not pursuing a collaboration, do we? Granted the technology in the CGM field is transforming rapidly with a number of players present so picking a particular company may be difficult at the moment.
reply; reality bites dexcom lost 23 cents a share last quarter.
investor.shareholder.com/dexcom/sec.cfm?DocType=Quarterly&Year=&FormatFilter=
|
|
|
Post by cm5 on Jul 16, 2016 12:19:33 GMT -5
More to the naysayers about Mannkind's corporate officers, employees, and leadership-- Here some real info about how Olivier Brandicourt views pharmaceuticals---see the link below theorizing about what he was assigned to accomplish, as well as some telling quotes that are very hard to find on-line--- Five big challenges facing Sanofi’s new chief Olivier Brandicourt, from FT: next.ft.com/content/8cb2611a-b900-11e4-b8e6-00144feab7deBelow are quoted statements by Olivier Brandicourt illustrative of his approach/views---My editorial comments---Really, Valeant? Really, an OTC branded laxative and an OTC branded cough medicine?
|
|
|
Post by urwayismine2 on Jul 16, 2016 13:23:43 GMT -5
Hi,
i've been watching this failure to market for some time now. i work in a building with over 5,000 people daily. if i posted something in the break rooms on each floor...do you think it might have an impact ?
is there a discount coupon for Afrezza ?
Thanks
|
|
|
Post by urwayismine2 on Jul 16, 2016 13:26:54 GMT -5
totally agree. Desisto becomes available in Sept 2016 if i recall correctly
|
|
|
Post by agedhippie on Jul 16, 2016 14:43:52 GMT -5
it is my understanding there are approximately 150 thousand Continuous Glucose Monitors being used? The money is in the tubing/sensor replacements.
quote: Despite MNKD 2.0 transparency not turning out to be as touted, I dont see any reason why MNKD cant announce that pursuit of a collaboration is central to the relaunch. We dont know if MNKD is or is not pursuing a collaboration, do we? Granted the technology in the CGM field is transforming rapidly with a number of players present so picking a particular company may be difficult at the moment.
reply; reality bites dexcom lost 23 cents a share last quarter.
The 150,000 number is Dexcom CGMs globally. and not just in the US. Under the FDA a Dexcom receiver must be replaced annually. The consumables for a G5 are the transmitter (4 per year) and the sensors (9 boxes of 4 sensors).The self-funding spend in a year splits: - $900 for receiver - $2,500 for transmitters - $2,700 for sensors Total annual cost: $6,100 The economics of the matter are quite clear. Giving someone 4 test strips a day costs the insurer $700 per year, giving them a CGM costs $6,100 per year. No prizes for guessing the insurers' choice with Medicare leading the way!
|
|
|
Post by agedhippie on Jul 16, 2016 14:47:01 GMT -5
Hi, i've been watching this failure to market for some time now. i work in a building with over 5,000 people daily. if i posted something in the break rooms on each floor...do you think it might have an impact ? Yes - your HR department will have a cow that someone is advertising prescription drugs and the potential liability. If you do it make sure no one know it was you.
|
|
|
Post by sportsrancho on Jul 16, 2016 15:04:36 GMT -5
Hi, i've been watching this failure to market for some time now. i work in a building with over 5,000 people daily. if i posted something in the break rooms on each floor...do you think it might have an impact ? Yes - your HR department will have a cow that someone is advertising prescription drugs and the potential liability. If you do it make sure no one know it was you. What's the difference between a flyer and a T-shirt saying the same thing?
|
|
|
Post by mnkdfann on Jul 16, 2016 15:20:15 GMT -5
totally agree. Desisto becomes available in Sept 2016 if i recall correctly I find the speculation about Desisto interesting. What has he been doing since his hire at Mnkd fell through? Is he just sitting at home collecting unemployment, waiting for a call from Mannkind? No other compny wanted / wants him? Or did some other company hire him, even though ( apparently) everyone knows he is moving to Mnkd asap?
|
|
|
Post by surplusvalue on Jul 16, 2016 16:27:37 GMT -5
it is my understanding there are approximately 150 thousand Continuous Glucose Monitors being used? The money is in the tubing/sensor replacements.
quote: Despite MNKD 2.0 transparency not turning out to be as touted, I dont see any reason why MNKD cant announce that pursuit of a collaboration is central to the relaunch. We dont know if MNKD is or is not pursuing a collaboration, do we? Granted the technology in the CGM field is transforming rapidly with a number of players present so picking a particular company may be difficult at the moment.
reply; reality bites dexcom lost 23 cents a share last quarter.
The 150,000 number is Dexcom CGMs globally. and not just in the US. Under the FDA a Dexcom receiver must be replaced annually. The consumables for a G5 are the transmitter (4 per year) and the sensors (9 boxes of 4 sensors).The self-funding spend in a year splits: - $900 for receiver - $2,500 for transmitters - $2,700 for sensors Total annual cost: $6,100 The economics of the matter are quite clear. Giving someone 4 test strips a day costs the insurer $700 per year, giving them a CGM costs $6,100 per year. No prizes for guessing the insurers' choice with Medicare leading the way! If Afrezza works best with CGM's then its clear why MNKD has been recommending/promoting CGM use despite the costs for the user. Mike was asking everyone to sign the petition regarding CGM use and dosing so its clear that they see its importance for Afrezza. I assumed that those reading my post understood that I was discussing collaboration not just recommendation of use and noted the issues with this as well. No question at the moment that the economics are problematic especially in the US where the health care provisions for supplying a CGM to a patient are restrictive (less so in other places where national heath care systems are more amenable). Perhaps that needs to change with changes in how far the US nationalizes health care to meet the demands of a population with an expansive diabetes problem. Dexcom and Medtronic are well known. Abbott is fighting for a share of this. Senseonics just got EU approval and San Meditech in China is a growing concern. The field and players as I said in my post are expanding. No doubt there will be more and this may have the effect of lowering costs.
|
|
|
Post by agedhippie on Jul 16, 2016 17:24:01 GMT -5
Yes - your HR department will have a cow that someone is advertising prescription drugs and the potential liability. If you do it make sure no one know it was you. What's the difference between a flyer and a T-shirt saying the same thing? A T-Shirt is personal, a noticeboard is potentially corporate. Companies tend to be very wary about this as it's just not worth the potential legal entanglements that can follow. There is the risk of the company being tied to the advert and since it's a prescription drug that's nasty. In reality the company could probably defend it but that's going to take time and resources (I don't have much to do with FDA actions but I spend a fair amount of time fighting with the FTC).
|
|
|
Post by agedhippie on Jul 16, 2016 17:38:56 GMT -5
If Afrezza works best with CGM's then its clear why MNKD has been recommending/promoting CGM use despite the costs for the user. Mike was asking everyone to sign the petition regarding CGM use and dosing so its clear that they see its importance for Afrezza. I assumed that those reading my post understood that I was discussing collaboration not just recommendation of use and noted the issues with this as well. No question at the moment that the economics are problematic especially in the US where the health care provisions for supplying a CGM to a patient are restrictive (less so in other places where national heath care systems are more amenable). Perhaps that needs to change with changes in how far the US nationalizes health care to meet the demands of a population with an expansive diabetes problem. Dexcom and Medtronic are well known. Abbott is fighting for a share of this. Senseonics just got EU approval and San Meditech in China is a growing concern. The field and players as I said in my post are expanding. No doubt there will be more and this may have the effect of lowering costs. I don't think it has ever been proven that Afrezza works better with a CGM. What has happened is the social media Afrezza users with CGMs can post graphs of their numbers and pictures always get more attention. From that a belief has grown that you need a CGM to best use Afrezza and I can see no reason why that should be the case. In my view as an Afrezza user you should be less likely to need a CGM. National health systems are far more restrictive about the use of CGMs than the US. It is difficult to get a CGM and the acceptance criteria are extremely restricted. In most countries it requires regional sign-off to issue a CGM which is a big deal. I don't think France allows them at all. CGMs need to be around an order of magnitude cheaper than they are today to get taken up generally by the national health systems.
|
|
|
Post by brentie on Jul 16, 2016 21:01:11 GMT -5
If Afrezza works best with CGM's then its clear why MNKD has been recommending/promoting CGM use despite the costs for the user. Mike was asking everyone to sign the petition regarding CGM use and dosing so its clear that they see its importance for Afrezza. I assumed that those reading my post understood that I was discussing collaboration not just recommendation of use and noted the issues with this as well. No question at the moment that the economics are problematic especially in the US where the health care provisions for supplying a CGM to a patient are restrictive (less so in other places where national heath care systems are more amenable). Perhaps that needs to change with changes in how far the US nationalizes health care to meet the demands of a population with an expansive diabetes problem. Dexcom and Medtronic are well known. Abbott is fighting for a share of this. Senseonics just got EU approval and San Meditech in China is a growing concern. The field and players as I said in my post are expanding. No doubt there will be more and this may have the effect of lowering costs. I don't think it has ever been proven that Afrezza works better with a CGM. What has happened is the social media Afrezza users with CGMs can post graphs of their numbers and pictures always get more attention. From that a belief has grown that you need a CGM to best use Afrezza and I can see no reason why that should be the case. In my view as an Afrezza user you should be less likely to need a CGM.National health systems are far more restrictive about the use of CGMs than the US. It is difficult to get a CGM and the acceptance criteria are extremely restricted. In most countries it requires regional sign-off to issue a CGM which is a big deal. I don't think France allows them at all. CGMs need to be around an order of magnitude cheaper than they are today to get taken up generally by the national health systems. I think Al would agree with the aged one...... The bottom line is always costs. Will patients get insurance coverage for Afrezza? Al: We're working with the reimbursement advisory panels to make sure we're within 5% of the current costs of Humalog and Novolog — so people will get essentially the same reimbursement they get now. We believe that we'll be covered by most mainstream health plans within six months of launch. Don't forget this also saves a lot of money because you don't need nearly as many expensive test strips for fingersticks, by an order of magnitude. For Type 2s, maybe they'll just need a fasting test once a week. If you're Type 1, you will want to do a few more.
www.healthline.com/diabetesmine/the-truth-about-afresa-inhalable-insulin-a-chat-with-al-mann#5
|
|
|
Post by rockstarrick on Jul 16, 2016 22:18:18 GMT -5
About Trustee: If you remember, on april or may, there Was a huge volume on a down day. I dont remember exactly the volume and i cannot see it on my iPad, but Was really huge. Those days were the ones when Matt done the famous diluition just after the ER or close to it. A lot of ppl were speculating about family selling their shares. Volume was really big and probably they already sold, but, to be honest i hope they don't. It will not surprise If they did, but just to remember that day of huge volume. have a nice weekend op I had this all written down but its on my work computer. I thought Al Man had around 132,000,0000 of shares between himself and the Mann Foundation.. I think it would be aggressive speculation if they got rid of a 1/3 to this point. Oh and more importantly there would be short shares available every where if they were sold. 153.2 million data.cnbc.com/quotes/MNKD/tab/8used to be 151.1, not sure when it changed but it did.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2016 22:49:07 GMT -5
If Afrezza works best with CGM's then its clear why MNKD has been recommending/promoting CGM use despite the costs for the user. Mike was asking everyone to sign the petition regarding CGM use and dosing so its clear that they see its importance for Afrezza. I assumed that those reading my post understood that I was discussing collaboration not just recommendation of use and noted the issues with this as well. No question at the moment that the economics are problematic especially in the US where the health care provisions for supplying a CGM to a patient are restrictive (less so in other places where national heath care systems are more amenable). Perhaps that needs to change with changes in how far the US nationalizes health care to meet the demands of a population with an expansive diabetes problem. Dexcom and Medtronic are well known. Abbott is fighting for a share of this. Senseonics just got EU approval and San Meditech in China is a growing concern. The field and players as I said in my post are expanding. No doubt there will be more and this may have the effect of lowering costs. I don't think it has ever been proven that Afrezza works better with a CGM. What has happened is the social media Afrezza users with CGMs can post graphs of their numbers and pictures always get more attention. From that a belief has grown that you need a CGM to best use Afrezza and I can see no reason why that should be the case. In my view as an Afrezza user you should be less likely to need a CGM. National health systems are far more restrictive about the use of CGMs than the US. It is difficult to get a CGM and the acceptance criteria are extremely restricted. In most countries it requires regional sign-off to issue a CGM which is a big deal. I don't think France allows them at all. CGMs need to be around an order of magnitude cheaper than they are today to get taken up generally by the national health systems.How much do they cost the patient right now? Source?
|
|